In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002
| Autor: | B. Johnson, Tim M. Stevens, David H. Wu, Samuel K. Bouchillon, Daryl J. Hoban, Patricia A. Bradford, Michael J. Dowzicky |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Microbiology (medical)
medicine.drug_class Antibiotics Minocycline Microbial Sensitivity Tests Tigecycline Gram-Positive Bacteria medicine.disease_cause Glycylcycline Microbiology Middle East South Africa Drug Resistance Bacterial Gram-Negative Bacteria Humans Medicine Gram-Positive Bacterial Infections Antibacterial agent biology business.industry Pseudomonas aeruginosa General Medicine Antimicrobial biology.organism_classification Anti-Bacterial Agents Europe Infectious Diseases Enterococcus Staphylococcus aureus Gram-Negative Bacterial Infections business medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 51:291-295 |
| ISSN: | 0732-8893 |
| Popis: | Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa , was 1 μg/mL, including vancomycin-resistant enterococci–, extended-spectrum β-lactamase–, and methicillin-resistant Staphylococcus aureus –resistant phenotypes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect